Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disruptive Innovations Conference

  • 96 views
Uploaded on

Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disruptive Innovations Conference

Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disruptive Innovations Conference

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
96
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disruptive Innovations Conference Reston, Virginia, September 3, 2013 – Aptiv Solutions, a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials, will chair the Adaptive Trial Designs Summit in Boston, MA on September 18.Presentations by scientists at Merck, Biogen Idec, Tufts, Harvard, Aptiv Solutions, and former regulatory officials will address how to overcome barriers to the adoption of adaptive designs. Adaptive clinical trialsallow pre-planned modifications to improve utility, such as terminating studies early to spare patients from ineffective treatments or in Phase II trials adding patients to effective dosages for a more accurate determination of the dose–response relationship. Coupled with new industry initiatives to increase efficiency, adaptive designs can make structural improvements to the drug development process. However, despite industry-wide acknowledgement of the promise of adaptive designs, only 20 percent of clinical trials are adaptive. Low adoption can be attributed significantly to internal organization resistance and perceived regulatory barriers, according to a recently released Tufts Center for the Study of Drug Development (CSDD) report. The success story of overcoming barriers to adoption of adaptive designs at Merck will be the subject of a talk by Jerald Schindler, VP of Late Development Statistics at Merck. He will recount his strategic approach to achieve broad organizational support for adaptive trial designs and the value this has generated. Additional talks will address: Regulatory obstacles to use of adaptive design, Simon Day, Director of Clinical Trials Consulting and Training Limited Product development decision-making with adaptive design, Stacy Lindborg, Senior Director of Biostatistics at Biogen Idec and Steven Zelenkofske, SVP Clinical and Medical Affairs & CMO at Regado Biosciences Sophisticated adaptive designs and how to approach them, Judith Quinlan, Senior VP Aptiv Solutions Innovation Centre Independent data monitoring committees, Lee Jen Wei, Professor at Harvard University A panel discussion on combining adaptive design with industry initiatives to drive clinical efficiency AboutAptiv Solutions Aptiv Solutions is a global development services company that is focused on enhancing clinical trial decision-making, efficiency and productivity in the pharmaceutical, biotech and medical device markets. The company offers clients an extensive portfolio of innovative services including adaptive clinical trials, translational research services, regulatory services, pharmacovigilance, clinical staffing and the operational support of a global clinical research organization. Aptiv Solutions has more than 850
  • 2. professionals in North America, Eastern & Western Europe, Israel, and Japan. Visit the website at www.aptivsolutions.com.